Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q4 2019 Results - Earnings Call Transcript

Feb. 27, 2020 10:22 PM ETCoherus BioSciences, Inc. (CHRS)2 Comments
SA Transcripts profile picture
SA Transcripts

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET

Company Participants

David Arrington - Vice President of Investor Relations & Corporate Affairs

Dennis Lanfear - Chief Executive Officer

Jean Viret - Chief Financial Officer

Vince Anicett - Chief Operating Officer

Thomas Fitzpatrick - Chief Legal Officer

Conference Call Participants

Mohit Bansal - Citigroup

Douglas Tsao - H.C. Wainwright

Mike Wolff - Baird

Ekaterina Knyazkova - JP Morgan Chase & Co

Salim Syed - Mizuho Securities

Michael Okunewitch - Maxim Group


Ladies and gentlemen, thank you for standing by and welcome to the Coherus BioSciences 2019 Fourth Quarter Earnings Conference Call. My name is May and I will be your conference operator for the call today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded.

I would now like to turn the call over to David Arrington, Vice President of Investor Relations and Corporate Affairs. Please go ahead.

David Arrington

Thank you, May, and good afternoon everyone. After close of market today, we issued a press release on our fourth quarter and year-end financial results. This release can be found on the Coherus BioSciences website. Joining me for today's call will be Denny Lanfear, Coherus' CEO; Dr. Jean Viret, Chief Financial Officer; Vince Anicett, Chief Operating Officer; and Tom Fitzpatrick, Chief Legal Officer.

Before we begin our formal remarks, I would like to remind you that we will be making forward-looking statements with respect to product development plans, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ from these statements. A description of these risks can be found on our most recent filings with the SEC.

In addition, Coherus BioSciences does not

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.